# A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

> **NCT04641247** · PHASE2 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 30 (estimated)

## Conditions studied

- Ovarian Neoplasms
- Breast Neoplasms

## Interventions

- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT04641247
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-16
- **Primary completion:** 2026-11-13
- **Final completion:** 2026-11-13
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04641247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04641247, "A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04641247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*